{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:41:08Z","timestamp":1760838068821,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bmc.2021.116250","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T19:10:48Z","timestamp":1623006648000},"page":"116250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma"],"prefix":"10.1016","volume":"42","author":[{"given":"Ozlem Ozen","family":"Karakus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116250_b0005","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2021.116250_b0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yapd.2011.03.011","article-title":"Neuroblastoma","volume":"58","author":"Colon","year":"2011","journal-title":"Adv Pediatr"},{"key":"10.1016\/j.bmc.2021.116250_b0015","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pbc.21354","article-title":"Changing trends of research and treatment in infant neuroblastoma","volume":"49","author":"Friedman","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bmc.2021.116250_b0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1517\/14728222.2014.867946","article-title":"Therapeutic targets for neuroblastomas","volume":"18","author":"Brodeur","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmc.2021.116250_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MPH.0b013e318299d637","article-title":"Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy","volume":"35","author":"Morgenstern","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bmc.2021.116250_b0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2174\/1567205010666131212110948","article-title":"Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors","volume":"17","author":"Fruci","year":"2016","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bmc.2021.116250_b0035","first-page":"1757","article-title":"Vandetanib inhibits cisplatinresistant neuroblastoma tumor growth and invasion","volume":"39","author":"Li","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bmc.2021.116250_b0040","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2015.05.004","article-title":"The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro","volume":"364","author":"Piskareva","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2021.116250_b0045","doi-asserted-by":"crossref","first-page":"15810","DOI":"10.1073\/pnas.1106030108","article-title":"Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET","volume":"108","author":"Schlessinger","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmc.2021.116250_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.25200","article-title":"Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy","volume":"62","author":"Streby","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bmc.2021.116250_b0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1148\/rg.2016150099","article-title":"MIBG in Neuroblastoma Diagnostic Imaging and Therapy","volume":"36","author":"Sharp","year":"2016","journal-title":"Radiographics"},{"key":"10.1016\/j.bmc.2021.116250_b0060","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1021\/acs.jmedchem.9b00386","article-title":"Novel Meta-iodobenzylguanidine-Based Copper Thiosemicarbazide-1-guanidinomethylbenzyl Anticancer Compounds Targeting Norepinephrine Transporter in Neuroblastoma","volume":"62","author":"Zhang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/189135","article-title":"Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective","volume":"2015","author":"Kayano","year":"2015","journal-title":"Sci World J"},{"key":"10.1016\/j.bmc.2021.116250_b0070","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1021\/acs.jmedchem.8b01123","article-title":"isoDGR-Peptides for Integrin Targeting: Is the Time Up for RGD?","volume":"61","author":"Holtke","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0075","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1021\/jm500092w","article-title":"Pharmacophoric modifications lead to superpotent alphavbeta3 integrin ligands with suppressed alpha5beta1 activity","volume":"57","author":"Neubauer","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2021.116250_b0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/cb2004725","article-title":"Small-molecule-modified surfaces engage cells through the alphavbeta3 integrin","volume":"7","author":"Klim","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2021.116250_b0090","doi-asserted-by":"crossref","first-page":"39805","DOI":"10.1038\/srep39805","article-title":"A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins","volume":"7","author":"Kapp","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2021.116250_b0095","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0100","first-page":"179","article-title":"Tumor angiogenesis targeting using imaging agents","volume":"45","author":"Weber","year":"2001","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.bmc.2021.116250_b0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pharmtox-010510-100512","article-title":"Membrane receptor for thyroid hormone: physiologic and pharmacologic implications","volume":"51","author":"Davis","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2021.116250_b0110","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/OTT.S67393","article-title":"Nanotetrac targets integrin alphavbeta3 on tumor cells to disorder cell defense pathways and block angiogenesis","volume":"7","author":"Davis","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bmc.2021.116250_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4939-7902-8_7","article-title":"Demonstration of the Receptor Site for Thyroid Hormone on Integrin alphavbeta3","volume":"1801","author":"Lin","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2021.116250_b0120","doi-asserted-by":"crossref","first-page":"E1238","DOI":"10.1152\/ajpendo.00480.2009","article-title":"Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor","volume":"297","author":"Davis","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bmc.2021.116250_b0125","first-page":"407","article-title":"Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model","volume":"25","author":"Mousa","year":"2006","journal-title":"Int Angiol"},{"key":"10.1016\/j.bmc.2021.116250_b0130","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1210\/en.2005-1390","article-title":"Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated","volume":"147","author":"Mousa","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.bmc.2021.116250_b0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vph.2009.10.007","article-title":"Thyroid hormone and angiogenesis","volume":"52","author":"Luidens","year":"2010","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.bmc.2021.116250_b0140","unstructured":"Mousa SA. Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders US; 2017."},{"key":"10.1016\/j.bmc.2021.116250_b0145","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/14756366.2011.557023","article-title":"Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: new anti-angiogenesis analogs","volume":"26","author":"Bridoux","year":"2011","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0150","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.4161\/cc.8.21.9963","article-title":"Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)","volume":"8","author":"Glinskii","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmc.2021.116250_b0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10456-007-9088-7","article-title":"Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor","volume":"11","author":"Mousa","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bmc.2021.116250_b0160","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2009-1926","article-title":"Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid","volume":"95","author":"Yalcin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bmc.2021.116250_b0165","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1021\/acs.bioconjchem.9b00742","article-title":"Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin alphavbeta3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme","volume":"30","author":"Rajabi","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0170","unstructured":"Mousa SA, Rajabi M, Karakus OO. Composition and method for dual targeting in treatment of neuroendocrine tumors, US; 2019."},{"key":"10.1016\/j.bmc.2021.116250_b0175","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1021\/acs.jmedchem.0c00537","article-title":"Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin alphavbeta3 Receptors in the Treatment of Neuroblastoma","volume":"63","author":"Karakus","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116250_b0180","unstructured":"Mousa SA, Rajabi M. Non-Cleavable Polymer Conjugated with \u03b1V\u03b23 Integrin Thyroid Antagonists, US; 2019."},{"key":"10.1016\/j.bmc.2021.116250_b0185","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood.V80.10.2539.2539","article-title":"Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor","volume":"80","author":"Kouns","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2021.116250_b0190","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/bj0630601","article-title":"Synthesis of some possible metabolites of thyroxine and triiodothyronine","volume":"63","author":"Wilkinson","year":"1956","journal-title":"Biochem J"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:13:32Z","timestamp":1760836412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621002583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"alternative-id":["S0968089621002583"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116250","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116250"}}